Compare Stocks → get a piece of the profit from this land (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CYTTNASDAQ:NVCTNASDAQ:RLMDNASDAQ:RZLT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTTCyteir Therapeutics$3.01-0.3%$3.01$1.65▼$3.19$108.35M0.08N/A551,300 shsNVCTNuvectis Pharma$6.15-5.8%$7.64$5.92▼$18.65$112.89M0.4591,717 shs110,339 shsRLMDRelmada Therapeutics$3.34-4.3%$4.37$2.36▼$7.22$100.78M0.2798,677 shs46,958 shsRZLTRezolute$2.64+3.1%$2.57$0.72▼$3.69$105.94M1.29268,366 shs213,986 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTTCyteir Therapeutics0.00%0.00%0.00%+300,999,900.00%+300,999,900.00%NVCTNuvectis Pharma0.00%-3.91%-8.48%-18.22%-63.82%RLMDRelmada Therapeutics0.00%-5.38%-22.33%-40.25%+7.74%RZLTRezolute0.00%-11.71%-20.00%+95.56%+22.79%get a piece of the profit from this land (Ad)This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land.Click here to see my #1 investment for 2024.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYTTCyteir TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANVCTNuvectis Pharma2.5734 of 5 stars3.51.00.00.02.85.00.0RLMDRelmada Therapeutics3.0586 of 5 stars2.02.00.04.42.61.70.6RZLTRezolute2.8867 of 5 stars3.53.00.00.01.85.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTTCyteir TherapeuticsN/AN/AN/AN/ANVCTNuvectis Pharma3.00Buy$21.00241.46% UpsideRLMDRelmada TherapeuticsN/AN/A$25.00648.50% UpsideRZLTRezolute3.00Buy$8.80233.33% UpsideCurrent Analyst RatingsLatest CYTT, NVCT, RZLT, and RLMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2024RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.005/8/2024NVCTNuvectis PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.004/18/2024RZLTRezoluteJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$7.004/18/2024RZLTRezoluteJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.004/9/2024RZLTRezoluteMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.003/7/2024RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00(Data available from 5/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTTCyteir TherapeuticsN/AN/AN/AN/A$4.13 per shareN/ANVCTNuvectis PharmaN/AN/AN/AN/A$0.76 per shareN/ARLMDRelmada TherapeuticsN/AN/AN/AN/A$2.39 per shareN/ARZLTRezoluteN/AN/AN/AN/A$1.77 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTTCyteir Therapeutics-$46.06M-$0.94N/A∞N/AN/A-24.88%-23.83%N/ANVCTNuvectis Pharma-$22.26M-$1.41N/AN/AN/AN/A-141.57%-103.98%8/14/2024 (Estimated)RLMDRelmada Therapeutics-$98.79M-$3.13N/AN/AN/AN/A-102.09%-91.30%8/13/2024 (Estimated)RZLTRezolute-$51.79M-$1.14N/AN/AN/AN/A-60.90%-54.58%9/12/2024 (Estimated)Latest CYTT, NVCT, RZLT, and RLMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/19/2024Q4 2023RLMDRelmada Therapeutics-$0.88-$0.84+$0.04-$0.84N/AN/A3/5/2024Q4 2023NVCTNuvectis Pharma-$0.40-$0.41-$0.01-$0.41N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYTTCyteir TherapeuticsN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTTCyteir TherapeuticsN/A21.8921.89NVCTNuvectis PharmaN/A3.463.46RLMDRelmada TherapeuticsN/A6.826.82RZLTRezoluteN/A11.8212.00OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTTCyteir Therapeutics63.24%NVCTNuvectis Pharma96.77%RLMDRelmada Therapeutics45.24%RZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipCYTTCyteir Therapeutics14.40%NVCTNuvectis Pharma38.85%RLMDRelmada Therapeutics18.00%RZLTRezolute20.80%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCYTTCyteir Therapeutics4636.00 million30.81 millionN/ANVCTNuvectis Pharma1318.36 million11.23 millionNot OptionableRLMDRelmada Therapeutics2030.17 million24.74 millionOptionableRZLTRezolute5740.13 million31.78 millionNot OptionableCYTT, NVCT, RZLT, and RLMD HeadlinesRecent News About These CompaniesMay 18 at 5:36 AM | americanbankingnews.comRezolute (NASDAQ:RZLT) Rating Reiterated by HC WainwrightMay 17 at 2:45 PM | markets.businessinsider.comBuy Rating on Rezolute: Unrecognized Potential in DME Treatment and Advancements in RZ358 for HyperinsulinismMay 17 at 2:45 PM | markets.businessinsider.comBuy Rating Affirmed on Rezolute’s Solid Financials and Advancing Clinical TrialsMay 16 at 7:58 PM | markets.businessinsider.comBuy Rating Affirmed for Rezolute Amidst Clinical Progress and Market OpportunityMay 16 at 2:57 PM | finanznachrichten.deRezolute, Inc.: Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business UpdateMay 16 at 12:39 PM | marketbeat.comRezolute's (RZLT) "Buy" Rating Reiterated at HC WainwrightMay 16 at 12:06 AM | investorplace.comRZLT Stock Earnings: Rezolute Misses EPS for Q3 2024May 15, 2024 | globenewswire.comRezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business UpdateMay 12, 2024 | nasdaq.comRezolute, Inc. Common Stock (NV) (RZLT) NewsMay 10, 2024 | finance.yahoo.comRezolute, Inc. (NASDAQ:RZLT) has caught the attention of institutional investors who hold a sizeable 47% stakeMay 9, 2024 | marketbeat.comVivo Capital LLC Raises Position in Rezolute, Inc. (NASDAQ:RZLT)April 27, 2024 | marketbeat.comVivo Capital LLC Has $7.13 Million Position in Rezolute, Inc. (NASDAQ:RZLT)April 24, 2024 | marketbeat.comFederated Hermes Inc. Purchases 3,544,053 Shares of Rezolute, Inc. (NASDAQ:RZLT)April 23, 2024 | globenewswire.comPhase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual MeetingApril 19, 2024 | msn.comJonesTrading Initiates Coverage of Rezolute (RZLT) with Buy RecommendationApril 18, 2024 | markets.businessinsider.comOptimistic Buy Rating for Rezolute’s RZ402 Drug Candidate Amid Promising DME Treatment ProspectsApril 15, 2024 | investorplace.comCan You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?April 10, 2024 | benzinga.comRezolute Stock (NASDAQ:RZLT), Analyst Ratings, Price Targets, PredictionsApril 4, 2024 | insidermonkey.comInsiders Are Buying These 5 Penny StocksMarch 27, 2024 | finance.yahoo.comRezolute Reaches US$75m Market Cap Benefiting Insider Stock BuyingMarch 26, 2024 | insidertrades.com3 Stocks Insiders Are Buying That Analysts Love (RZLT)New MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCyteir TherapeuticsNASDAQ:CYTTCyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.Nuvectis PharmaNASDAQ:NVCTNuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.Relmada TherapeuticsNASDAQ:RLMDRelmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.RezoluteNASDAQ:RZLTRezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.